Tigermed concludes share repurchase program, announces management changes

Hangzhou Tigermed Consulting (SZSE:300347) announced the conclusion of its share repurchase program, initiated in early 2024. The company repurchased 9,806,300 A shares, accounting for 1.1337% of the total share capital and 1.3219% of the A shares, at a total cost of CNY 500,116,483.34. The repurchased shares will be used for future equity incentives, employee stock ownership plans, and reducing registered capital.